Plasma Adrenomedullin and Obstructive Sleep Apnea

Robert Wolk, Anna Svatikova, Maria E. Otto, Michal S. Hoffmann, Carolyn J. Duenwald, Virend K. Somers

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Background: Obstructive sleep apnea (OSA) is associated with hypertension. The vasorelaxing peptide adrenomedullin (ADM) may counteract effects of OSA-induced release of vasopressor substances. Methods: Plasma ADM levels were measured at 9:30 PM, 2:00 AM (after 4 to 5 h of untreated OSA), and 6:00 AM (after 4 h of continuous positive airway pressure treatment) in 15 OSA patients and in 10 controls. Results: Baseline ADM levels were similar in the OSA and control groups (28.7 ± 6.7 v 27.7 ± 6.4 pg/mL, respectively), did not change overnight in either group, and were not affected by continuous positive airway pressure. Conclusions: OSA does not exert any significant acute or chronic effects on plasma ADM levels.

Original languageEnglish (US)
Pages (from-to)74-76
Number of pages3
JournalAmerican journal of hypertension
Issue number1
StatePublished - Jan 2004


  • Adrenomedullin
  • Continuous positive airway pressure
  • Sleep apnea

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Plasma Adrenomedullin and Obstructive Sleep Apnea'. Together they form a unique fingerprint.

Cite this